GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biora Therapeutics Inc (NAS:BIOR) » Definitions » Cyclically Adjusted FCF per Share

Biora Therapeutics (Biora Therapeutics) Cyclically Adjusted FCF per Share : $0.00 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Biora Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Biora Therapeutics's adjusted free cash flow per share data for the fiscal year that ended in Dec. 2023 was $-3.081. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-30), Biora Therapeutics's current stock price is $ 0.6046. Biora Therapeutics's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec. 2023 was $0.00. Biora Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Biora Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Biora Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biora Therapeutics Cyclically Adjusted FCF per Share Chart

Biora Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial - - - - -

Biora Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biora Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Biora Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biora Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biora Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biora Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Biora Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biora Therapeutics's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-3.081/129.4194*129.4194
=-3.081

Current CPI (Dec. 2023) = 129.4194.

Biora Therapeutics does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate it.


Biora Therapeutics  (NAS:BIOR) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Biora Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Biora Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biora Therapeutics (Biora Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
4330 La Jolla Village Drive, Suite 300, San Diego, CA, USA, 92122
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States.
Executives
Athyrium Opportunities Iii Co-invest 1 Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Surbhi Sarna director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Aditya P. Mohanty director, officer: Chief Executive Officer 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Ann Howe director C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Athyrium Capital Management, Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Fund (a) Lp 10 percent owner 605 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10158
Hutan Hashemi officer: Chief Compliance Officer 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Damon Silvestry officer: Chief Operating Officer 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Jeffrey D. Alter director 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Iii Acquisition Lp 10 percent owner 505 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10017
Harry Stylli director, officer: Chairman & CEO 3595 JOHN HOPKINS CT, SAN DIEGO CA 92121
Matthew T Cooper officer: Chief Scientific Officer 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Advisers Llc 10 percent owner 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Gp Llc 10 percent owner 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Lp 10 percent owner 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104